Paid Clinical Trials Bakersfield
Discover 67 paid clinical trials in Bakersfield, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
FF/UMEC/VI vs. FF/VIA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Sponsor:
GlaxoSmithKline
Location:
Code:
NCT05757102
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
FF/UMEC/VI
ELLIPTA
FF/VI
BI 764524A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
Sponsor:
Boehringer Ingelheim
Location:
Code:
NCT06321302
Conditions
Diabetic Retinopathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BI 764524
Sham comparator to BI 764524
Aflibercept (Eylea®) - US only
BEM/RZR vs. SOF/VELC-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Sponsor:
Atea Pharmaceuticals, Inc.
Location:
Code:
NCT06868264
Conditions
HEPATITIS C VIRUS CHRONIC INFECTION
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Sofosbuvir-Velpatasvir (SOF/VEL)
BarzolvolimabA Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Sponsor:
Celldex Therapeutics
Location:
Code:
NCT06455202
Conditions
Chronic Spontaneous Urticaria
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
barzolvolimab
Matching placebo
PovorcitinibA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Sponsor:
Incyte Corporation
Location:
Code:
NCT05851443
Conditions
Moderate to Severe Asthma
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
povorcitinib
placebo
ICS-LABA
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Sacituzumab TirumotecanA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06637423
Conditions
Non-Muscle Invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab tirumotecan
RGX-314RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
Sponsor:
AbbVie
Location:
Code:
NCT04567550
Conditions
Diabetic Retinopathy (DR)
Center-Involved Diabetic Macular Edema (CI-DME)
Eligibility Criteria
Sex: All
Age: 25 - 70+
Healthy Volunteers: Not accepted
Interventions
ABBV-RGX-314 Dose 1
ABBV-RGX-314 Dose 2
ABBV-RGX-314 Dose 3
Topical Steroid
ABBV-RGX-314 Dose 4
ZH9A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Sponsor:
Prokarium Ltd
Location:
Code:
NCT06181266
Conditions
NMIBC
High Risk NMIBC
Non Muscle Invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
ZH9
OPN-375OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
Sponsor:
Optinose US Inc.
Location:
Code:
NCT03747458
Conditions
Bilateral Nasal Polyposis
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
OPN-375
Cretostimogene GrenadenorepvecPhase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Sponsor:
CG Oncology, Inc.
Location:
Code:
NCT06567743
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cretostimogene Grenadenorepvec